- Home
- BFLY vs XERS Comparison
BFLY vs XERS Comparison
Compare BFLY & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BFLY | XERS |
|---|---|---|
| Founded | 2011 | 2005 |
| Country | United States | United States |
| Employees | 220 | N/A |
| Industry | Medical Electronics | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | BFLY | XERS |
|---|---|---|
| Price | $4.48 | $6.18 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 6 |
| Target Price | $5.00 | ★ $10.83 |
| AVG Volume (30 Days) | ★ 4.4M | 1.6M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 100.00 |
| EPS | N/A | ★ 0.01 |
| Revenue | N/A | ★ $49,590,000.00 |
| Revenue This Year | $24.01 | $34.37 |
| Revenue Next Year | $19.93 | $22.86 |
| P/E Ratio | ★ N/A | $633.00 |
| Revenue Growth | N/A | ★ 142.67 |
| 52 Week Low | $1.32 | $4.30 |
| 52 Week High | $5.72 | $10.08 |
Technical Indicators
Market Signals| Indicator | BFLY | XERS |
|---|---|---|
| Relative Strength Index (RSI) | 50.75 | 48.72 |
| Support Level | $3.66 | $5.81 |
| Resistance Level | $5.00 | $6.41 |
| Average True Range (ATR) | 0.25 | 0.27 |
| MACD | 0.04 | -0.01 |
| Stochastic Oscillator | 77.66 | 40.48 |
Price Performance
Historical ComparisonAbout BFLY Butterfly Network Inc.
Butterfly Network Inc is a digital health business transforming care with handheld, whole-body ultrasound. Powered by its proprietary Ultrasound-on-Chip technology, its solution enables the acquisition of imaging information from an affordable, powerful device that fits in a healthcare professional's pocket with a combination of cloud-connected software and hardware technology that is easily accessed through a mobile application. Butterfly iQ+ is an ultrasound device that can perform whole-body imaging in a single handheld probe using semiconductor technology. The company operates in one reportable segment, which includes all activities related to the development, manufacture, and sale of the Company's products, software, and other services.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.